Final Glance: Biotechnology companies
AP - Wed Jun 11, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed Jun 11, 12:20PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Wed Jun 11, 9:34AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Critical Alerts For JC Penney, Brown Forman, Schlumberger, Celgene, and DirecTV Technology Released By InvestorsObserver
PR Newswire - Wed Jun 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for JCP, BF.B, SLB, CELG, and DTV.
Oral OTEZLA(R) (Apremilast) Showed Long-Term Clinical Benefits in Patients with Active Psoriatic Arthritis
Business Wire - Wed Jun 11, 6:30AM CDT
--OTEZLA demonstrated a consistent safety profile with no clinically meaningful changes in laboratory measurements across three PALACE phase III studies of 1,493 patients over 52 weeks
Oral OTEZLA(R) (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Naive Patients with Active Psoriatic Arthritis
Business Wire - Wed Jun 11, 6:30AM CDT
--PALACE 4 is the first and only large randomized, placebo-controlled study to examine the efficacy and safety of a single agent in patients naive to previous DMARD therapy
Agios Initiates Trial on AG-348 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 3:35PM CDT
Agios Pharmaceuticals, Inc. (AGIO) announced the initiation of a multiple ascending dose (MAD) phase I trial on pipeline candidate AG-348.
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 08, 8:00AM CDT
What a week for the major indexes! The S&P 500 and Dow both ended at record highs. The success of the broader markets paled in comparison to a handful of health-care stocks, though. One of this week's soaring stocks received good news from...
Jim Cramer: No Joy in Shortville
at The Street - Fri Jun 06, 12:42PM CDT
Shorts take much more homework than longs.
Health Care Sector Equities Coverage -- Research on Neurocrine Biosciences, PDL BioPharma, Celgene, and Array BioPharma
PR Newswire - Fri Jun 06, 6:50AM CDT
On Thursday, June 05, 2014, the NASDAQ Composite ended at 4,296.23, up 1.05%, the Dow Jones Industrial Average finished the session at 16,836.11, up 0.59% and the S&P 500 closed at 1,940.46, up 0.65%. During the trading session, all of the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.16% higher at 695.40, and the index has advanced 0.32% in the previous three months. Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), PDL BioPharma Inc. (NASDAQ: PDLI), Celgene Corp. (NASDAQ: CELG) and Array BioPharma Inc. (NASDAQ: ARRY). Free technical research on NBIX, PDLI, CELG and ARRY can be downloaded upon signing up at:
'Mad Money' Lightning Round: I'm Flying With American
at The Street - Fri Jun 06, 5:00AM CDT
Cramer is a believer in Charles Schwab and likes Gilead Sciences and Celgene.
Jim Cramer's 'Mad Money' Recap: Follow Your Own Investment Path
at The Street - Thu Jun 05, 7:08PM CDT
Investors need to be their own gurus and decide for themselves when it's time to buy and sell.
3 Reasons Why Wall Street Hates Merrimack Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Jun 05, 12:43PM CDT
A rising short interest is often times a bad omen for a stock. Specifically, the high degree of risk involved in shorting tends to ensure that short-sellers have a clear cut investing thesis for why a particular stock is overvalued. Merrimack...